GRI Bio Reports Q2 2026 Financial Results with Reduced Net Loss and Increased Cash Reserves

GRI Bio, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $1.6 million, a decrease from a net loss of $2.9 million in the same period of 2025. For the six months ending June 30, 2026, the company recorded a net loss of $3.6 million, down from $5.9 million in the prior year. Total operating expenses for the second quarter were $1.6 million, significantly lower than the $2.9 million reported in the same quarter of the previous year, primarily due to reduced research and development costs associated with the completion of the Phase 2a clinical trial for its lead product candidate, GRI-0621.

The company’s cash and cash equivalents increased to approximately $10.9 million as of June 30, 2026, compared to $8.2 million at the end of 2025. This increase was bolstered by net proceeds of $7.8 million from financing activities, primarily from an At The Market Offering (ATM) that raised $8.2 million in gross proceeds. GRI Bio has sold a total of 1,748,549 shares under the ATM agreement at a weighted average price of $8.22 per share, contributing to its liquidity position. The company’s accumulated deficit reached $55.3 million as of June 30, 2026.

In terms of operational developments, GRI Bio has made significant strides in its clinical programs. The FDA granted Orphan Drug Designation to GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF) on June 18, 2026. The company is also preparing for further clinical trials, having recently completed a Phase 2a trial that met its primary endpoint of safety and tolerability. The trial involved 35 patients, with preliminary results indicating that GRI-0621 was well-tolerated and showed potential anti-fibrotic effects.

The company’s workforce has expanded, with a total of 2,186,115 shares of common stock outstanding as of June 30, 2026, up from 497,693 shares at the end of 2025. This increase reflects the issuance of shares through various financing activities, including the ATM offering. GRI Bio continues to focus on its research and development efforts, particularly for GRI-0621 and its other product candidate, GRI-0803, which targets autoimmune disorders.

Looking ahead, GRI Bio anticipates that its existing cash reserves will be sufficient to fund operations through the second quarter of 2027, assuming it continues with preliminary work on additional clinical studies for GRI-0621. However, the company acknowledges the need for substantial additional capital to conduct further clinical studies and is exploring various financing options, including equity securities and potential collaborations. The company also faces challenges related to its market value, as it currently does not meet the Nasdaq continued listing requirement of maintaining a market value of at least $5 million, which could impact its ability to raise future capital.